Compugen (CGEN) Stock Price & Analysis
CGEN Stock Chart & Stats
- Day’s Range
- ILA 623.20 - ILA 623.20
- 52-Week Range
- ILA 460.80 - ILA 924.00
- Previous Close
- ILA 630.50
- Volume
- 16.79K
- Average Volume (3M)
- 29.77K
- Market Cap
- ILS 589.80M
- Enterprise Value
- ILS 80.25M
- Total Cash (Recent Filing)
- ILS 125.30M
- Total Debt (Recent Filing)
- ILS 3.02M
- Price to Earnings (P/E)
- 5.1
- Beta
- 1.01
- Next Earnings
- Nov 09, 2026 (Est.)
- EPS Estimate
- -25.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Discovery Platform
The Unigen platform has already generated multiple immuno-oncology targets grounded in human disease biology, providing Compugen with a repeatable source of potential candidates. This platform capability can support future pipeline replenishment and strengthen the company’s strategic value to larger pharmaceutical partners over time.
Extended Cash Runway And Low Leverage
A cash runway extending into 2029 and no debt give Compugen meaningful financial flexibility to advance clinical programs without near-term financing pressure. This reduces balance-sheet risk and allows management to pursue development milestones while preserving negotiating capacity with potential partners.
Partnered Pipeline And Royalty Potential
Compugen’s partnered assets provide access to large pharmaceutical development capabilities while retaining potential milestone and royalty economics. Gilead payments and AstraZeneca’s expanding Phase III program create multiple routes to future value realization beyond Compugen’s internal clinical spending.
Bears Say
Lumpy Revenue And Ongoing Losses
The company remains dependent on modest collaboration-related revenue while continuing to report quarterly net losses, and recent revenue growth partly reflects milestone recognition. This makes earnings power less predictable and leaves sustained operations reliant on cash reserves and future partnership receipts.
Exploratory MAIA Trial Limits Regulatory Impact
MAIA’s small, exploratory design may generate useful clinical signals but is unlikely by itself to provide the statistical or regulatory evidence normally required for approval. A favorable interim result could therefore still require follow-up studies, extending development timelines and funding needs.
Dependence On Partner Execution
A substantial portion of Compugen’s potential economic value depends on programs controlled and advanced by AstraZeneca and Gilead. Delays, changing partner priorities, or unsuccessful clinical outcomes could postpone milestone receipts and royalties, limiting the company’s ability to convert its discovery assets into durable revenue.
Compugen News
CGEN FAQ
What was Compugen’s price range in the past 12 months?
What is Compugen’s market cap?
When is Compugen’s upcoming earnings report date?
How were Compugen’s earnings last quarter?
Is Compugen overvalued?
Does Compugen pay dividends?
What is Compugen’s EPS estimate?
How many shares outstanding does Compugen have?
What happened to Compugen’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Compugen?
What is the TipRanks Smart Score and how is it calculated?
Compugen Stock Smart Score
Company Description
Compugen
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors. COM902, a therapeutic antibody designed to target TIGIT, which is also in Phase I clinical trials as a monotherapy for advanced malignancies. Bapotulimab, an antibody targeting ILDR2, presently in Phase I clinical development for solid tumor indications. AZD2936, an innovative bispecific antibody targeting both TIGIT and PD-1, advancing through Phase I/II clinical studies for patients with advanced or metastatic non-small cell lung cancer. Additionally, Compugen maintains earlier-stage immuno-oncology programs, with a particular emphasis on myeloid targets. To further its research and development, Compugen actively fosters strategic alliances. It has a collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics that modulate immune checkpoint regulators. Another key partnership is with Bristol-Myers Squibb, aimed at evaluating the safety and tolerability of COM701 when administered alongside Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company also collaborates with Johns Hopkins School of Medicine to investigate novel T cell and myeloid checkpoint targets, and has a distinct research collaboration with Johns Hopkins University specifically dedicated to myeloid science. Furthermore, Compugen holds a licensing agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Eran Ophir
- Employees
- 75
- Website
- cgen.com
- Address
- Azrieli Center, Holon, TA, 5885849, IL
Compugen (CGEN) Earnings & Revenues
CGEN Earnings Call
Earnings Call SentimentPositive
The call conveyed measurable progress across Compugen's pipeline and partnerships — notable trial milestones (MAIA interim due Q1 2027), encouraging partner data (rilvegostomig ASCO OS signal), strengthened cash runway into 2029, and material milestone/royalty upside from Gilead and AstraZeneca. Offsetting these positives are key uncertainties: MAIA's exploratory design and lowered control-arm PFS benchmark, absence of pre-readout FDA engagement, early-stage status and limited visibility for GS-0321 data, dependency on partner execution for value realization, and continued modest absolute revenues with ongoing net losses. Overall, the fundamentals improved and near-term clinical and financial visibility increased, but meaningful regulatory and partner-driven milestones remain future-dependent.
View all IL:CGEN earnings summariesCGEN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 1 | 0 | 11 |
